Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

News Releases

Date Title and Summary
Toggle Summary electroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference
BASKING RIDGE, N.J. , May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger , Chief Executive Officer, will be available at Little Grapevine™ (
Toggle Summary electroCore Announces First Quarter Financial Results
Generated first quarter revenue of $734,000 Secured FDA clearance of gammaCore ™ (nVNS) label expansion for migraine prevention Announced initiatives to support the potential use of nVNS for the treatment of symptoms associated with COVID-19 Company to host conference call and webcast today, May
Toggle Summary electroCore to Announce First Quarter Ended March 31, 2020 Financial Results on Thursday, May 14
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , May 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of
Toggle Summary electroCore Provides Update on COVID-19 Clinical Initiatives
Randomized controlled investigator-initiated trial (IIT) of non-invasive vagus nerve stimulation (nVNS) therapy currently enrolling COVID-19 patients in Spain Peer-reviewed paper, “Use of Non-Invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated with COVID-19: A Theoretical
Toggle Summary electroCore Provides Business Update and Select First Quarter 2020 Guidance
BASKING RIDGE, N.J. , April 17, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020.
Toggle Summary electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in the U.K.
ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020 BASKING RIDGE, N.J. , April 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service ( NHS ) has exercised its option to
Toggle Summary electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19
BASKING RIDGE, N.J. , April 02, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) to facilitate
Toggle Summary electroCore Announces 510(k) Clearance of gammaCore™ Label Expansion into Migraine Prevention
Approval makes novel non-invasive vagus nerve stimulation therapy available for prevention as well as acute treatment of migraines in adults BASKING RIDGE, N.J. , March 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced
Toggle Summary electroCore Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital
BASKING RIDGE, N.J. , March 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into a common stock purchase agreement of up to $25 million with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a
Toggle Summary electroCore Announces Changes to its Board of Directors
John Gandolfo, Tom Patton and Peter Cuneo to join the Board, adding significant medical technology operational, financial and turn-around experience BASKING RIDGE, N.J. , March 26, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today